Evotec SEEVO +1.11%64 Net Margin % is -77.84% as of Mar. 2026. GuruFocus rates EVO with a GF Score™ of 64/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Evotec SE ranks worse than 83.16% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Evotec SE's Net Income for the
three
months ended in Mar. 2026 was $-141.0 Mil. Evotec SE's Revenue for the
three
months ended in Mar. 2026 was $181.1 Mil. Therefore, Evotec SE's net margin for the quarter that ended in Mar. 2026 was -77.84%.
The historical rank and industry rank for Evotec SE's Net Margin % or its related term are showing as below:
EVO'
s Net Margin % Range Over the Past 10 Years
Min: -26.02 Med: 4.9 Max: 34.87
Current: -26.02
EVO's Net Margin % is ranked worse than 83.16% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs EVO: -26.02
Evotec SE (NAS:EVO) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Evotec SE Net Margin % Related Terms
Evotec SE Net Margin % Historical Data
* Premium members only.
The historical data trend for Evotec SE's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Net Margin % distribution charts can be found below:
* The bar in red indicates where Evotec SE's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (EVO) has a Net Margin % of -77.84% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Evotec SE and its competitors. According to the industry distribution chart, Evotec SE ranks #795 out of 956 companies in the Drug Manufacturers industry, placing it in the top 83.2%.
Is Evotec SE's Net Margin % too high?
Evotec SE's current Net Margin % is -77.84%. Based on the distribution chart, Evotec SE ranks #795 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evotec SE has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #795 out of 956 companies for Net Margin %. This places Evotec SE in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Net Margin % is -77.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $2.74 — trading 35.8% below its estimated fair value. The current Net Margin % is -77.84%. Evotec SE's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Evotec SE (EVO), the current Net Margin % is -77.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVO) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $2.74 is trading 35.8% below its estimated GF Value™ of $4.27.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for EVO:
Net Margin %: -77.84%
GF Value™: $4.27 vs. price of $2.74 (35.8% below fair value)
No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
64GF Score
Get the complete analysis for EVO
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVO has been successfully added to your 
